Atrial fibrillation guidelines into clinical practice

Professor Daniel Scherr co-chaired a very interesting symposium at the recent EHRA 2022 congress, how the can physicians better use the guidelines. We asked professor Scherr to summarize the most important take away messages from this symposium.

Recent developments of the conduction system pacing

Professor Hung-Fat Tse is an expert on the field on pacing, and recently co-chaired a very interesting symposium at the EHRA 2022 about the recent developments of conduction system pacing.

Conduction system pacing: ready for prime time?

Professor Mauro Biffi speak us about the data that were presented at the recent European Heart Rhythm Association meeting. The session he talking about was about conduction system pacing, a novel modality of cardiac stimulation.

What do new guidelines tell us about conduction system pacing?

Professor Michael Glikson co-chaired the European Society of Cardiology guidelines on cardiac pacing, and now he speaks for us about the part of this huge document that deals with conduction system pacing. What do the new guidelines tell us?

Antithrombotic Approaches to Reduce the Risk of Secondary Event in CAD and PAD

Professor Marc Bonaca co-moderated a session at the American College of Cardiology meeting that was focused on the care of patients with advanced vascular disease. Specifictly diseases in the lower extremities, the legs and the arms called peripheral arterial disease.

Results from the EMPULSE Trial

Professor Mikhail Kosiborod going to speaking about the additional analysis from the EMPULSE trial that were presented at the American College of Cardiology congress. The trial demonstrated the effects of empagliflozin on symptoms, physical limitations and quality of life in patients hospitalized for acute heart failure.

Effect of Sotagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes and Moderate Renal Impairment Who Are at Cardiovascular Risk - The SCORED Trial

Professor Deepak Bhatt had presented an analysis from the SCORED trial at the American College of Cardiology Annual Sessions as a late-breaking clinical trial.

Protecting comorbid patients with atrial fibrillation from stroke

Professor John Camm recently attended the European Heart Rhythm Association annual congress.  One of the session he involved in wanted to group together the challenging cases in the topic.

Bentracimab Immediately and Significantly Reverses the Antiplatelet Effects of Ticagrelor in Older People

Professor Deepak Bhatt gave us a brief recap of some data he presented at the ACC Late-Braker session. He presented data about a drug know as Bentracimab,which it is an investigational agent, a human monoclal antibody that it is been desigend to reverse the effect of the anti-platelet drug Ticagrelor.

EHRA scientific documents 2022

Professor Cecilia Linde gave us an update from the European Heart Rhythm Association conference from Copenhagen on four topics regarding the EHRA scientific documents. 1. Interaction between electrical implantable devices and medical procedures 2. Mitral valve prolapse 3. Novel oral anticoagulants, NOACs 4. Leadless Pacemaker

Guidance in Heart Failure Care at ACC 2022

Professor David Lanfear summarize the key interesting things from the American College of Cardiology 2022 Scientific sessions in the topic.

How to reduce limb events including amputations in our patients?

Professor Manesh Patel speak about how to reduce limb events, amputations and making our patients limbs to better with peripheral arterial disease.

Updated Cumulative Results of Treatment With Mavacamten From the EXPLORER-LTE Cohort of the MAVA-LTE Study

Florian Rader presented this year at ACC 2022 the results of the MAVA-LTE Study. As the backdrop of this study, Hypertrophic Cardiomyopathy is a disease known for now over 70 years, and in these years we haven't had any specific medication that targets the underline mechanism of this disorder.

SSaSS: Salt Substitute and Stroke Study into the effect of salt substitutes on cardiovascular events and death

Professor Bruce Neal introduce the Salt Substitute and Stroke Study, which defines the overall balance of benefits and risks of salt substitutes compared with  salt in terms of cardiovascular disease, including strokes and mortality.

2021 ESC Guidelines - CVD Prevention

Prof. Frank Visseren speaks about the 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice.

The current management of Angina

Prof. Marzilli speaks about the current management of Angina.

CLARIFY - In stable coronary disease, patients with angina and prior myocardial infarction have a poor prognosis despite adherence to guideline recommanded therapies. Final 5-year results from the CLARIFY study

SWEDEHEART: Secondary prevention medication after coronary artery bypass surgery and long-term mortality: A longitudinal population-based study from the SWEDEHEART registry

ICD use in HF - Association between implantable cardioverter-defibrillator use for primary prevention and mortality: a prospective propensity-score matched study

PURE: Impact of modifiable risk factors on cardiovascular disease and mortality

RAPIDTnT: A randomised trial of a 1-hour troponin T protocol in suspected acute coronary syndromes: the Rapid Assessment of Possible ACS In the emergency Department with high sensitivity Troponin T

ENTRUST-AF PCI - Edoxaban-based versus vitamin-K-antagonist-based anti-thrombotic regimen following successful coronary stenting in atrial fibrillation patients

POPular Genetics - Genotype-guided oral P2Y12-inhibition in patients with St-segment elevation myocardial infarction undergoing primary PCI : a randomized, open-label, multicenter trial

Combined effect of lower LDL-C and lower SBP on the lifetime risk od cardiovascular disease

AFIRE - Rivaroxaban monotherapy versus dual therapy in patients with atrial fibrillation and stable coronary artery disease

GALACTIC - Goal-directed AfterLoad Reduction in Acute Congestive Cardiac Decompensation: a randomized controlled trial

Salt substitution and community-wide reduction in blood pressure and hypertension incidence

HOPE 4 - Impact on cardiovascular risk of a community based multifaceted intervention in individuals with hypertension in 2 middle income countries: The Heart Outcomes Prevention and Evaluation 4 study

SYNTAXES: Ten-Year Survival after Coronary Artery Bypass Grafting versus Percutaneous Coronary Intervention: The SYNTAX Extended Survival study

MITRA-FR - 2 years follow-Up of the MITRA-FR study a randomized controlled trial evaluating the effectiveness of percutaneous mitral valve repair in secondary mitral regurgitation

DAPA HF The Dapagliflozin And Prevention Of Adverse-outcomes In Heart Failure Trial

CONDI-2/ERIC-PPCI Effect of remote ischemic conditioning on clinical outcomes in patients with Stsegment elevation myocardial infarction undergoing primary percutaneous coronary intervention